Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 20, 2007

Bavarian Nordic Achieves $25M Milestone from the HHS

  • Bavarian Nordic reports that it has reached another milestone in its agreement with the U.S. government and will thus receive $25 million. In June, the HHS contracted the firm to manufacture and deliver 20 million doses of its smallpox vaccine in a deal potentially worth $1.6 billion.

    This year, Bavarian Nordic has received $100 million in relation to this deal. The firm was reportedly paid $50 million in advance. It also received another $25 million milestone fee just three weeks ago.

    Next year, Bavarian Nordic expects to receive yet another milestone payment of $25 million.
    Imvamune is based on the Modified Vaccinia Ankara virus, a live virus but one that does not replicate in the body, according to the company.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »